Hydroxyl safflower yellow A regulates the tumor immune microenvironment to produce an anticancer effect in a mouse model of hepatocellular carcinoma

Ma,Yicong; Feng,Cuiling; Wang,Jingjing; Chen,Ziwei; Wei,Peng; Fan,Angran; Wang,Xu; Yu,Xue; Ge,Dongyu; Xie,Hua; Liu,Li; Zhang,Qian; Li,Xu‑Hui

doi:10.3892/ol.2019.9946

Hydroxyl safflower yellow A regulates the tumor immune microenvironment to produce an anticancer effect in a mouse model of hepatocellular carcinoma

Authors:
- Yicong Ma
- Cuiling Feng
- Jingjing Wang
- Ziwei Chen
- Peng Wei
- Angran Fan
- Xu Wang
- Xue Yu
- Dongyu Ge
- Hua Xie
- Li Liu
- Qian Zhang
- Xu‑Hui Li
View Affiliations

Affiliations: Institute of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, P.R. China, Department of Traditional Chinese Medicine, Peking University People's Hospital, Beijing 100044, P.R. China, Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang 314006, P.R. China
Published online on: January 18, 2019 https://doi.org/10.3892/ol.2019.9946
Pages: 3503-3510

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a serious threat to human health. Chemotherapy drugs such as cisplatin are widely used in cancer treatment, but can cause severe side effects. Hydroxyl safflower yellow A (HSYA) is a water‑soluble chalcone glycoside substance extracted from safflowers (Carthamus tinctorius L.) that has been reported to inhibit tumor growth with few side effects. The tumor immune microenvironment is crucial for the proliferation and invasiveness of tumor cells, and it is mediated by forkhead box P3‑positive (FOXP3+) regulatory T cells (Tregs) and retinoic acid receptor‑related orphan receptor‑γ (RORγ)‑expressing Th17 cells. FOXP3+ Tregs inhibit immunoreaction and FOXP3 is a key indicator of Tregs. RORγ isoform 2, also known as RORγt, is an important transcription factor in Th17 cells that may promote cancer progression. In the present study, the antitumor effect of HSYA on HCC was investigated, as well as its impact on the tumor immune microenvironment. Following the establishment of a mouse model for HCC, hematoxylin and eosin staining were performed to observe histological changes in liver tumors, and the spleen and thymus were weighed to calculate the spleen and thymus indexes. The proportion of FOXP3+ Tregs in the spleen was determined by flow cytometry, and expression levels of Foxp3 and Rorγt were examined by reverse transcription‑quantitative polymerase chain reaction and western blot analysis. The results of the present study showed that cisplatin inhibited tumor growth, caused weight loss and reduced the immunoreactivity of the mice. HSYA inhibited tumor growth without causing significant weight loss. The proportion of FOXP3‑expressing Tregs in the spleen and the expression of Foxp3 and Rorγt mRNA decreased following treatment with certain doses of HSYA. In conclusion, HSYA inhibited tumor growth without detrimental effects on the weight of the mice, indicating that HSYA may be suitable as a novel therapy for HCC patients.

View Figures

View References

1	Yang JD, Nakamura I and Roberts LR: The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Semin Cancer Biol. 21:35–43. 2011. View Article : Google Scholar : PubMed/NCBI
2	Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G, Yin Z, Xie X, Wang X, Chen W, et al: A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 28–Sep;2017.(Epub ahead of print).
3	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
4	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
5	Chen JG: Trends in the incidence of liver cancer and its primary prevention in China. J Clin Hepatol. 28:256–260. 2012.
6	Bruix J and Sherman M; American Association for the Study of Liver Diseases, : Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
7	Karaman B, Battal B, Sari S and Verim S: Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol. 20:18059–18060. 2014. View Article : Google Scholar : PubMed/NCBI
8	Greten TF, Wang XW and Korangy F: Current concepts of immune based treatments for patients with HCC: From basic science to novel treatment approaches. Gut. 64:842–848. 2015. View Article : Google Scholar : PubMed/NCBI
9	Mbeunkui F and Johann DJ Jr: Cancer and the tumor microenvironment: A review of an essential relationship. Cancer Chemother Pharmacol. 63:571–582. 2009. View Article : Google Scholar : PubMed/NCBI
10	Fritz JM, Dwyer-Nield LD and Malkinson AM: Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation. Mol Cancer. 10:762011. View Article : Google Scholar : PubMed/NCBI
11	Liu J, Zhang H, Jia L and Sun H: Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditions. Mol Med Rep. 11:1708–1714. 2015. View Article : Google Scholar : PubMed/NCBI
12	Mathai AM, Kapadia MJ, Alexander J, Kernochan LE, Swanson PE and Yeh MM: Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma. Am J Surg Pathol. 36:980–986. 2012. View Article : Google Scholar : PubMed/NCBI
13	Castro G, Liu X, Ngo K, De Leon-Tabaldo A, Zhao S, Luna-Roman R, Yu J, Cao T, Kuhn R, Wilkinson P, et al: RORγt and RORα signature genes in human Th17 cells. PLoS One. 12:e01818682017. View Article : Google Scholar : PubMed/NCBI
14	Liao R, Sun J, Wu H, Yi Y, Wang JX, He HW, Cai XY, Zhou J, Cheng YF, Fan J and Qiu SJ: High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res. 32:32013. View Article : Google Scholar : PubMed/NCBI
15	Zhang Q, Zheng J, Wang L, et al: Therapeutic effect of Ramosetron on preventing gastrointestinal reaction induced by chemotherapeutic drugs including Cisplatin in 80 cases. Chin Pharm. 10:1024–1025. 2007.
16	Liu ZQ, Cheng JT, Zhu HX, et al: Experimental study on increasing effect and decreasing its side-effect of Cisplatin of LiuJunZi decoction. Lishizhen Medicine and Materia Medical Research. 20:2492–2494. 2009.
17	Wu H, Lv SZ, Ying XZ, Ye YL and Tian ZF: Effect of traditional Chinese medicine in immunity recovery of radiotherapy in patients with liver cancer. Chin Archiv Trad Chin Med. 8:1997–1999. 2015.(In Chinese).
18	Wu QL, Lu HD, Guo XL and Kong QZ: Exploration of treatment of malignant tumors with Chinese herbs that invigorate the blood and remove stasis. J Int Trad Western Med. 5:530–531. 2010.
19	Zhou X, Tang L, Xu Y, Zhou G and Wang Z: Towards a better understanding of medicinal uses of Carthamus tinctorius L. in traditional Chinese medicine: A phytochemical and pharmacological review. J Ethnopharmacol. 151:27–43. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Wang P, Gui S, Li Y, Chen R, Zeng R, Zhao P, Wu H, Huang Z and Wu J: Hydroxysafflor yellow A attenuates the apoptosis of peripheral blood CD4⁺ T lymphocytes in a murine model of sepsis. Front Pharmacol. 8:6132017. View Article : Google Scholar : PubMed/NCBI
21	Xie H, Zhang Q, Zhao YQ, Cui W and Niu X: The experiment of safflor yellow effecting the cell growth cycle of mouse H22 grafting tumor. China J Tradit Chin Med Pharm. 171–173. 2006.(In Chinese).
22	Ma L, Liu L, Ma Y, Xie H, Yu X, Wang X, Fan A, Ge D, Xu Y, Zhang Q and Song C: The role of E-cadherin/β-catenin in hydroxysafflor yellow A inhibiting adhesion, invasion, migration and lung metastasis of hepatoma cells. Biol Pharm Bull. 40:1706–1715. 2017. View Article : Google Scholar : PubMed/NCBI
23	Xi S, Zhang Q, Xie H, Liu L, Liu C, Gao X, Zhang J, Wu L, Qian L and Deng X: Effects of hydroxy safflor yellow A on blood vessel and mRNA expression with VEGF and bFGF of transplantation tumor with gastric adenocarcinoma cell line BGC-823 in nude mice. Zhongguo Zhong Yao Za Zhi. 34:605–610. 2009.(In Chinese). PubMed/NCBI
24	Wang J, Zhang Q, Gu LG, Cui W, Xie H and Niu XY: Effect of hydroxy safflor yellow A on the cell cycle and apoptosis of human umbilical vein endothelial cells with the stimulus of tumor cell conditioned medium. J Beijing Univ Tradit Chin Med. 31:741–744. 2008.(In Chinese).
25	Xi SY, Zhang Q, Liu CY, et al: Effects of hydroxy safflower yellow A on the expression of bFGF protein and MMP-9 in human gastric cancer xenografts. Chin J Chin Materia. 21:2877–2881. 2010.(In Chinese).
26	Xi SY, Zhang Q, Liu CY, Xie H, Yue LF, Li WD, Zang BX and Gao XM: Effects of HSYA on protein and mRNA expression of KDR, HIF-1α and protein expression of VEGF in nude mice with BGC-823 transplantation tumor. Chin J Trad Chin Med Pharm. 27:82–87. 2012.
27	Limani P, Borgeaud N, Linecker M, Tschuor C, Kachaylo E, Schlegel A, Jang JH, Ungethüm U, Montani M, Graf R, et al: Selective portal vein injection for the design of syngeneic models of liver malignancy. Am J Physiol Gastrointest Liver Physiol. 310:G682–G688. 2016. View Article : Google Scholar : PubMed/NCBI
28	Lu YM and Zhang H: Effects of electroacupuncture on T-lymphocytes, spleen index, thymus index and lymphopoiesis levels in strenuous exercise-induced stress rat. Zhen Ci Yan Jiu. 37:136–139. 2012.PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Dong F, Xue C, Wang Y, Peng Y, Zhang Y, Jin M and Zang B: Hydroxysafflor yellow A attenuates the expression of inflammatory cytokines in acute soft tissue injury. Sci Rep. 7:405842017. View Article : Google Scholar : PubMed/NCBI
31	Min J and Wei C: Hydroxysafflor yellow A cardioprotection in ischemia-reperfusion (I/R) injury mainly via Akt/hexokinase II independent of ERK/GSK-3β pathway. Biomed Pharmacother. 87:419–426. 2017. View Article : Google Scholar : PubMed/NCBI
32	Wang T, Duan SJ, Wang SY, Lu Y, Zhu Q, Wang LJ and Han B: Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia. Physiol Behav. 147:193–197. 2015. View Article : Google Scholar : PubMed/NCBI
33	Sun L, Yang L, Xu YW, Liang H, Han J, Zhao RJ and Cheng Y: Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood-brain barrier disruption. Brain Res. 1473:227–235. 2012. View Article : Google Scholar : PubMed/NCBI
34	Wu XL: Efficacy enhancing effect of Shikonin on human liver cancer HepG2 cells treated by Cisplatin. Chin Med J Res Prac. 31:35–38. 2017.(In Chinese).
35	Wu Y and Liu R: Study on the drug-resistant reversal effects of ginsenoside Rh2 in human hepatocellular carcinoma HepG2/ADM cells and its mechanism. J Med Postgra. 30:476–480. 2017.
36	Park HR, Ju EJ, Jo SK, Jung U, Kim SH and Yee ST: Enhanced antitumor efficancy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 9:852009. View Article : Google Scholar : PubMed/NCBI
37	Liu Y, Jing Y, Guo LL, et al: Effects of Guben Zhike Recipe on the spleen index, thymus index and Th1/Th2 unbalance in COPD mice. China J Tradit Chin Med Pharm. 2015.(In Chinese).
38	Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG and Rudensky AY: Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 22:329–341. 2005. View Article : Google Scholar : PubMed/NCBI
39	Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, et al: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 132:2328–2339. 2007. View Article : Google Scholar : PubMed/NCBI
40	Lin SZ, Chen KJ, Xu ZY, Chen H, Zhou L, Xie HY and Zheng SS: Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3⁺ regulatory T cells. Cancer Prev Res (Phila). 6:594–602. 2013. View Article : Google Scholar : PubMed/NCBI
41	Takeuchi Y and Nishikawa H: Roles of regulatory T cells in cancer immunity. Int Immunol. 28:401–409. 2016. View Article : Google Scholar : PubMed/NCBI
42	Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP and Zheng L: Increased intratumoral IL17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 50:980–989. 2009. View Article : Google Scholar : PubMed/NCBI
43	Huang Y, Wang F, Wang Y, Zhu Z, Gao Y, Ma Z, Xu R and Du Z: Intrahepatic interleukin-17⁺ T cells and FoxP3⁺ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 29:851–859. 2014. View Article : Google Scholar : PubMed/NCBI
44	Lin ZW, Wu LX, Xie Y, Ou X, Tian PK, Liu XP, Min J, Wang J, Chen RF, Chen YJ, et al: The expression levels of transcription factors T-bet, GATA-3, RORγt and FOXP3 in peripheral blood lymphocyte (PBL) of patients with liver cancer and their significance. Int J Med Sci. 12:7–16. 2015. View Article : Google Scholar : PubMed/NCBI